Outcomes of Hypothermia in Addition to Decompressive Hemicraniectomy in Treatment of Malignant Middle Cerebral Artery Stroke: A Randomized Clinical Trial.


Journal

JAMA neurology
ISSN: 2168-6157
Titre abrégé: JAMA Neurol
Pays: United States
ID NLM: 101589536

Informations de publication

Date de publication:
01 05 2019
Historique:
pubmed: 19 1 2019
medline: 18 2 2020
entrez: 19 1 2019
Statut: ppublish

Résumé

Moderate hypothermia in addition to early decompressive hemicraniectomy has been suggested to further reduce mortality and improve functional outcome in patients with malignant middle cerebral artery (MCA) stroke. To investigate whether moderate hypothermia vs standard treatment after early hemicraniectomy reduces mortality at day 14 in patients with malignant MCA stroke. This randomized clinical trial recruited patients from August 2011 through September 2015 at 6 German university hospitals with dedicated neurointensive care units. Of the patients treated with hemicraniectomy and assessed for eligibility, patients were randomly assigned to either standard care or moderate hypothermia. Data analysis was completed from December 2016 to June 2018. Moderate hypothermia (temperature, 33.0 ± 1.0°C) was maintained for at least 72 hours immediately after hemicraniectomy. The primary outcome was mortality rate at day 14 compared with the Fisher exact test and expressed as odds ratio (ORs) with 95% CIs. Rates of patients with serious adverse events were estimated for the period of the first 14 days after hemicraniectomy and 12 months of follow-up. Secondary outcome measures included functional outcome at 12 months. Of the 50 study participants, 24 were assigned to standard care and 26 to moderate hypothermia. Twenty-eight were male (56%); the mean (SD) patient age was 51.3 (6.6) years. Recruitment was suspended for safety concerns: 12 of 26 patients (46%) in the hypothermia group and 7 of 24 patients (29%) receiving standard care had at least 1 serious adverse event within 14 days (OR, 2.05 [95% CI, 0.56-8.00]; P = .26); after 12 months, rates of serious adverse events were 80% (n = 20 of 25) in the hypothermia group and 43% (n = 10 of 23) in the standard care group (hazard ratio, 2.54 [95% CI, 1.29-5.00]; P = .005). The mortality rate at day 14 was 19% (5 of 26 patients) in the hypothermia group and 13% (3 of 24 patients) in the group receiving standard care (OR, 1.65 [95% CI, 0.28-12.01]; P = .70). There was no significant difference regarding functional outcome after 12 months of follow-up. In patients with malignant MCA stroke, moderate hypothermia early after hemicraniectomy did not improve mortality and functional outcome compared with standard care, but may cause serious harm in this specific setting. http://www.drks.de, identifier DRKS00000623.

Identifiants

pubmed: 30657812
pii: 2721091
doi: 10.1001/jamaneurol.2018.4822
pmc: PMC6515837
doi:

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

571-579

Commentaires et corrections

Type : ErratumIn
Type : CommentIn

Références

Arch Neurol. 1984 Jan;41(1):26-9
pubmed: 6606414
N Engl J Med. 2002 Feb 21;346(8):557-63
pubmed: 11856794
Int J Stroke. 2017 Oct;12(7):732-740
pubmed: 28350280
Neurosurgery. 2009 Jan;64(1):86-92; discussion 92-3
pubmed: 19050656
Int J Stroke. 2015 Aug;10(6):941-9
pubmed: 26148223
Arch Neurol. 1996 Apr;53(4):309-15
pubmed: 8929152
N Engl J Med. 2015 Dec 17;373(25):2403-12
pubmed: 26444221
Lancet Neurol. 2009 Oct;8(10):949-58
pubmed: 19747656
Stroke. 2014 Apr;45(4):1222-38
pubmed: 24481970
Exp Neurol. 2008 Aug;212(2):386-92
pubmed: 18538766
Stroke. 2009 Dec;40(12):e657-65
pubmed: 19762706
N Engl J Med. 2002 Feb 21;346(8):549-56
pubmed: 11856793
Stroke. 2007 May;38(5):1585-9
pubmed: 17363720
JAMA. 2018 Dec 4;320(21):2211-2220
pubmed: 30357266
Stroke. 2010 Oct;41(10):2265-70
pubmed: 20724711
JAMA. 2013 Nov 27;310(20):2174-83
pubmed: 24105303
J Korean Neurosurg Soc. 2018 Mar;61(2):267-276
pubmed: 29526071
Int J Stroke. 2013 Jul;8(5):383-7
pubmed: 23782729
N Engl J Med. 2016 Dec 22;375(25):2457-2467
pubmed: 28002714
Stroke. 1984 May-Jun;15(3):492-6
pubmed: 6729878
Stroke. 2016 Dec;47(12):2888-2895
pubmed: 27834742
Cerebrovasc Dis. 2006;21(1-2):79-85
pubmed: 16330868
Brain. 2007 Dec;130(Pt 12):3063-74
pubmed: 17478443
Stroke. 2007 Sep;38(9):2506-17
pubmed: 17690311
Int J Stroke. 2011 Feb;6(1):79-86
pubmed: 21205246
Lancet Neurol. 2007 Mar;6(3):215-22
pubmed: 17303527
Neurocrit Care. 2015 Feb;22(1):146-64
pubmed: 25605626
Stroke. 2001 Sep;32(9):2117-23
pubmed: 11546905
J Cereb Blood Flow Metab. 2016 Jul;36(7):1157-64
pubmed: 27089911

Auteurs

Hermann Neugebauer (H)

Department of Neurology, RKU-University and Rehabilitation Hospitals Ulm, University of Ulm, Ulm, Germany.

Hauke Schneider (H)

Department of Neurology, University Hospital, Technische Universität Dresden, Dresden, Germany.
Department of Neurology, Universitätsklinikum Augsburg, Augsburg, Germany.

Julian Bösel (J)

Department of Neurology, University of Heidelberg, Heidelberg, Germany.
Department of Neurology, Klinikum Kassel, Kassel, Germany.

Carsten Hobohm (C)

Department of Neurology, University of Leipzig, Leipzig, Germany.
Klinikum Saalekreis, Merseburg, Germany.

Sven Poli (S)

Department of Neurology, University of Tübingen, Tübingen, Germany.

Rainer Kollmar (R)

Department of Neurology, University of Erlangen, Erlangen, Germany.
Department of Neurology and Neurointensive Care, Klinikum Darmstadt, Darmstadt, Germany.

Jan Sobesky (J)

Department of Neurology and Center for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Department of Neurology, Johanna-Etienne-Krankenhaus Neuss, Neuss, Germany.

Stefan Wolf (S)

Department of Neurosurgery, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Miriam Bauer (M)

Center for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Sascha Tittel (S)

Institute of Statistics, University of Ulm, Ulm, Germany.

Jan Beyersmann (J)

Institute of Statistics, University of Ulm, Ulm, Germany.

Johannes Woitzik (J)

Department of Neurosurgery, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Peter U Heuschmann (PU)

Institute for Clinical Epidemiology and Biometry, Comprehensive Heart Failure Centre, University of Würzburg, Würzburg, Germany.
Clinical Trial Center, University Hospital Würzburg, Würzburg, Germany.

Eric Jüttler (E)

Department of Neurology, RKU-University and Rehabilitation Hospitals Ulm, University of Ulm, Ulm, Germany.
Department of Neurology, Ostalb-Klinikum Aalen, Aalen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH